Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-11-16T12:47:11.366Z Has data issue: false hasContentIssue false
  • English
  • Français

Assessment of mature serum brain-derived neurotrophic factor (BDNF) is not superior to total serum BDNF in prediction of antidepressant treatment outcome

Published online by Cambridge University Press:  23 March 2020

A. Eckert ,
T. Mikoteit ,
J. Beck ,
U.M. Hemmeter ,
S. Brand ,
K. Schmitt ,
R. Bischof ,
A. Delini-Stula  and
E. Holsboer-Trachsler
A. Eckert*
Affiliation:
Psychiatric University Clinics Basel, Neurobiology Lab for Brain Aging & Mental Health, Basel, Switzerland
T. Mikoteit
Affiliation:
Psychiatric University Clinics Basel, Center for Affective- Stress and Sleep Disorders ZASS, Basel, Switzerland
J. Beck
Affiliation:
Psychiatric University Clinics Basel, Center for Affective- Stress and Sleep Disorders ZASS, Basel, Switzerland
U.M. Hemmeter
Affiliation:
Psychiatric Service Canton of St. Gallen, Center of Education and Research COEUR, Wil SG, Switzerland
S. Brand
Affiliation:
Psychiatric University Clinics Basel, Center for Affective- Stress and Sleep Disorders ZASS- Department of Sport- Exercise and Health- Sport Science Division- Faculty of Medicine, Basel, Switzerland
K. Schmitt
Affiliation:
Psychiatric University Clinics Basel, Neurobiology Lab for Brain Aging & Mental Health, Basel, Switzerland
R. Bischof
Affiliation:
ADI International Institute for Advancement of Drug Development GmbH, ADI International Institute for Advancement of Drug Development GmbH, Basel, Switzerland
A. Delini-Stula
Affiliation:
ADI International Institute for Advancement of Drug Development GmbH, ADI International Institute for Advancement of Drug Development GmbH, Basel, Switzerland
E. Holsboer-Trachsler
Affiliation:
Psychiatric University Clinics Basel, Center for Affective- Stress and Sleep Disorders ZASS, Basel, Switzerland
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background

Serum BDNF levels are decreased in major depressive disorder (MDD) and tend to normalize under antidepressant treatment, serving as a treatment outcome predictor. BDNF is initially synthetized as precursor protein proBDNF and is cleaved to mature BDNF (mBDNF) while only the latter exerts neurotrophic activity.

Aim

The aim was to explore if a specific enzyme-linked immunosorbent assay (ELISA) kit for mBDNF in serum would be superior to the unspecific assessment of total serum BDNF in predicting treatment response in MDD.

Methods

Twenty-five patients with MDD underwent standardized treatment with duloxetine. Severity of depression was measured by Hamilton Depression Rating Scale (HDRS) at baseline (BL), after one (W1), two (W2) and six weeks (W6) of treatment. Treatment response was defined as a HDRS ≥ 50% reduction of BL score at W6. mBDNF and total BDNF serum levels were determined at BL, W1 and W2.

Results

A high and stable correlation was found between mBDNF and total BDNF serum levels over all measurements. The predictive value of mBDNF BL levels and mBDNFΔW1 to response was similar to that of total BDNF BL and total BDNFΔW1. The assessment of serum mBDNF was not superior to total BDNF in prediction of treatment outcome.

Conclusions

Not only baseline total BDNF but also mBDNF is predictive to treatment outcome. The later might represent the main player in this respect, which supports the idea of a functional link between neuroplasticity and MDD.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
EV495
Information
European Psychiatry , Volume 33 , Issue S1: Abstracts of the 24th European Congress of Psychiatry , March 2016 , pp. S410
Copyright
Copyright © European Psychiatric Association 2016
Submit a response

Comments

No Comments have been published for this article.